{"celex_id": "31997R0467", "reference": "13.3.1997\nEN\nOfficial Journal of the European Communities\nL 71/1\nCOUNCIL REGULATION (EC) No 467/97\nof 3 March 1997\nproviding for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization and specified products used for the manufacture of finished Pharmaceuticals and withdrawing duty-free treatment as pharmaceutical products from certain INNs whose predominant use is not pharmaceutical\nTHE COUNCIL OF THE EUROPEAN UNION,\nHaving regard to the Treaty establishing the European Community, and in particular Article 113 thereof,\nHaving regard to the proposal from the Commission,\nWhereas, in the course of the Uruguay Round negotiations the Community and a number of countries discussed duty-free treatment of pharmaceutical products;\nWhereas the participants in those discussions concluded that in addition to products falling within the Harmonized System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941, duty-free treatment should be given to designated pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization as well as specified salts, esters and hydrates of such INNs, and also to designated products used for the production and manufacture of finished products;\nWhereas the results of the discussions, as set out in the record of discussions, were incorporated into the tariff schedules of the participants annexed to the Marrakesh Protocol to GATT 1994;\nWhereas they also concluded that representatives of the WTO members party to the record of discussions would meet under the auspices of the Council for Trade in Goods of the WTO, normally at least once every three years — to review the product coverage with a view to including, by consensus, additional pharmaceutical products for tariff elimination;\nWhereas the first such review has taken place with the conclusion that a certain number of additional INNs and products used for production and manufacture of finished Pharmaceuticals should be granted duty-free treatment and that the list of specified prefixes and suffixes for salts and esters of INNs should be expanded;\nWhereas in the context of the review it was concluded that it was appropriate to rectify the situation with regard to certain INNs whose use was predominantly non-pharmaceutical and which had been inadvertently included among those INNs already receiving duty-free treatment,\nHAS ADOPTED THIS REGULATION:\nArticle 1\nFrom 1 April 1997 the Community shall also accord duty-free treatment for the INNs listed in Annex I as well as the salts, esters and hydrates of such products.\nArticle 2\nFrom 1 April 1997 the Community shall also grant duty-free treatment for the products used in the production and manufacture of pharmaceutical products listed in Annex II.\nArticle 3\nFrom 1 April 1997 the specified prefixes and suffixes of INNs eligible for duty-free treatment shall also include those listed in Annex III.\nArticle 4\nFrom 1 April 1997 the products listed in Annex IV together with the salts, esters and hydrates of such products shall no longer benefit from duty-free treatment.\nArticle 5\nThis Regulation shall enter into force on the day following that of its publication in the Official Journal of the European Communities.\nThis Regulation shall be binding in its entirety and directly applicable in all Member States.\nDone at Brussels, 3 March 1997.\nFor the Council\nThe President\nM. de Boer\nANNEX I\nAdditional INNs to receive duty-free treatment\nCN code\nCAS RN\nName\n2844 40 30\n113716-48-6\nIolopride (123 I)\n142481-95-6\nTechnetium (99m Tc) furifosmin\n2846 90 00\n131069-91-5\nGadoversetamide\n135326-11-3\nGadoxetic acid\n138721-73-0\nSprodiamide\n2914 40 90\n20098-14-0\nIdramantone\n2916 39 00\n71109-09-6\nVedaprofen\n2918 30 00\n22161-81-5\nDexketoprofen\n112665-43-7\nSeratrodast\n2918 90 90\n139403-31-9\nPimilprost\n2921 49 90\n136236-51-6\nRasagiline\n2922 49 70\n6582-31-6\nDapabutan\n2923 90 00\n1794-75-8\nLaurcetium bromide\n2924 10 00\n1675-66-7\nAdelmidrol\n62304-98-7\nThymalfasin\n132787-19-0\nTradecamide\n129009-83-2\nVersetamide\n2924 29 90\n147362-57-0\nLoviride\n94497-51-5\nTamibarotene\n2925 19 80\n144849-63-8\nBisnafide\n2925 20 00\n137159-92-3\nAptiganel\n2926 90 80\n137109-71-8\nBalazipone\n147076-36-6\nLaflunimus\n2928 00 90\n141579-54-6\nFenleuton\n2930 90 16\n87573-01-1\nSalnacedin\n2930 90 70\n90357-06-5\nBicalutamide\n112573-72-5\nDexecadotril\n107023-41-6\nPobilukast\n81110-73-8\nRacecadotril\n2931 00 50\n132236-18-1\nZifrosilone\n2931 00 80\n114084-78-5\nIbandronic acid\n124351-85-5\nIncadronic acid\n63132-39-8\nOlpadronic acid\n2932 99 70\n105674-77-9\nLanproston\n2932 99 90\n123407-36-3\nArteflene\n132017-01-7\nBervastatin\n110816-79-0\nCromoglicate lisetil\n149494-37-1\nEbalzotan\n151581-24-7\nIralukast\n113806-05-6\nOlopatadine\n139110-80-8\nZanamivir\n2933 29 90\n158682-68-9\nElisartan\n116684-92-5\nGaldansetron\n89371-44-8\nImidaprilat\n138402-11-6\nIrbesartan\n118072-93-8\nZoledronic acid\n2933 39 95\n119257-34-0\nBesipirdine\n118248-91-2\nFodipir\n155415-08-0\nInogatran\n121750-57-0\nItameline\n144412-49-7\nLamifiban\n155319-91-8\nMangafodipir\n150443-71-3\nNicanartine\n29876-14-0\nNicotredole\n144035-83-6\nPiclamilast\n137795-35-8\nSpiroglumide\n147025-53-4\nTalsaclidine\n149488-17-5\nTrovirdine\n2933 40 10\n127294-70-6\nBalofloxacin\n143383-65-7\nPremafloxacin\n143224-34-4\nTelinavir\n2933 40 90\n96946-42-8\nCisatracurium besilate\n158966-92-8\nMontelukast\n136668-42-3\nQuiflapon\n2933 59 70\n127266-56-2\nAdatanserin\n106941-25-7\nAdefovir\n113852-37-2\nCidofovir\n150756-35-7\nEfletirizine\n119687-33-1\nIganidipine\n127759-89-1\nLobucavir\n140945-32-0\nMapinastine\n134208-17-6\nMazapertine\n96604-21-6\nOcinaplon\n148504-51-2\nRipisartan\n115762-17-9\nRuzadolane\n118420-47-6\nTagorizine\n137234-62-9\nVoriconazole\n151319-34-5\nZaleplon\n2933 79 00\n148396-36-5\nFradafiban\n74436-00-3\nGeclosporin\n143943-73-1\nLirequinil\n106730-54-5\nOlprinone\n135548-15-1\nOxeclosporin\n145733-36-4\nTasosartan\n143343-83-3\nToborinone\n2933 90 95\n137882-98-5\nAbitesartan\n114607-46-4\nAcitazanolast\n120511-73-1\nAnastrozole\n134523-00-5\nAtorvastatin\n128270-60-0\nBivalirudin\n139481-59-7\nCandesartan\n54278-85-2\nCandocuronium iodide\n105806-65-3\nEfegatran\n62568-57-4\nEmideltide\n120081-14-3\nGoralatide\n142880-36-2\nIlornastat\n62732-44-9\nIpidacrine\n116287-14-0\nLanperisone\n112809-51-5\nLetrozole\n116644-53-2\nMibefradil\n136122-46-8\nMipitroban\n144702-17-0\nPomisartan\n132036-88-5\nRamosetron\n106308-44-5\nRufinamide\n144701-48-4\nTelmisartan\n147059-72-1\nTrovafloxacin\n2934 10 00\n149079-51-6\nCartasteine\n128312-51-6\nCinalukast\n51287-57-1\nDenotivir\n101001-34-7\nPamicogrel\n136433-51-7\nTazofelone\n138742-43-5\nZankiren\n2934 20 90\n144665-07-6\nLubeluzole\n150915-41-6\nPerospirone\n146939-27-7\nZiprasidone\n2934 90 60\n130370-60-4\nBatimastat\n133040-01-4\nEprosartan\n135202-79-8\nIlonidap\n114686-12-3\nImitrodast\n132418-36-1\nRocepafant\n132418-35-0\nSetipafant\n2934 90 70\n125533-88-2\nMofarotene\n127045-41-4\nPazufloxacin\n2934 90 80\n118292-40-3\nTazarotene\n2934 90 98\n151356-08-0\nAfovirsen\n138298-79-0\nAlnespirone\n152317-89-0\nAlniditan\n153420-96-3\nAtibeprone\n143393-27-5\nAzalanstat\n149908-53-2\nAzimilide\n150490-85-0\nBerupipam\n154361-50-9\nCapecitabine\n133099-04-4\nDarifenacin\n137500-42-6\nDarsidomine\n114030-44-3\nDexpemedolac\n115464-77-2\nElopiprazole\n141790-23-0\nFozivudine tidoxil\n122254-45-9\nGlenvastatin\n143443-90-7\nIfetroban\n82857-82-7\nIlepcimide\n104454-71-9\nIpenoxazone\n118288-08-7\nLafutidine\n138068-37-8\nLepirudin\n78994-23-7\nLevormeloxifene\n116476-16-5\nLevosemotiadil\n148152-63-0\nNapitane\n84558-93-0\nNetivudine\n147432-77-7\nOntazolast\n139225-22-2\nPanamesine\n103255-66-9\nPazinaclone\n123447-62-1\nPrulifloxacin\n131986-45-3\nXanomeline\n145781-32-4\nZolasartan\n2935 00 90\n147536-97-8\nBosentan\n136817-59-9\nDelavirdine\n119905-05-4\nDelequamine\n112966-96-8\nDomitroban\n125279-79-0\nErsentilide\n139133-26-9\nLexipafant\n154397-77-0\nNapsagatran\n139133-27-0\nNupafant\n116649-85-5\nRamatroban\n133276-80-9\nSamixogrel\n146623-69-0\nSaprisartan\n149556-49-0\nSusalimod\n144494-65-5\nTirofiban\n139308-65-9\nTolafentrine\n107753-78-6\nZafirlukast\n2936 29 90\n131875-08-6\nLexacalcitol\n2937 10 10\n9002-68-0\nFollitropin alfa\n152923-57-4\nLutropin alfa\n2937 22 00\n103466-73-5\nIcometasone enbutate\n2937 29 90\n144459-70-1\nRofleponide\n2937 99 00\n124478-60-0\nAglepristone\n140703-51-1\nExamorelin\n133107-64-9\nInsulin lispro\n144743-92-0\nTeverelix\n2939 50 90\n151581-23-6\nApaxifylline\n132210-43-6\nCipamfylline\n100324-81-0\nLisofylline\n98833-92-2\nStacofylline\n2939 90 90\n135905-89-4\nMirisetron\n117086-68-7\nRicasetron\n25775-90-0\nZucapsaicin\n2940 00 90\n133692-55-4\nSeprilose\n2941 90 00\n127785-64-2\nBasifungin\n116853-25-9\nCefluprenam\n122841-10-5\nCefoselis\n156131-91-8\nDimadectin\n123997-26-2\nEprinomectin\n149951-16-6\nLenapenem\n108852-90-0\nNemorubicin\n159445-62-2\nOrientiparcin\n156769-21-0\nSanfetrinem\n3001 90 99\n120993-53-5\nDesirudin\n3002 10 91\n143653-53-6\nAbciximab\n156227-98-4\nAfelimomab\n151763-64-3\nCapromab\n152923-56-3\nDacliximab\n145832-33-3\nDetumomab\n142864-19-5\nEnlimomab\n152981-31-2\nInolimomab\n150631-27-9\nNacolomab tafenatox\n159445-64-4\nOdulimomab\n147191-91-1\nPriliximab\n153101-26-9\nRegavirumab\n148189-70-2\nVotumumab\n3002 10 95\n143090-92-0\nAnakinra\n143631-61-2\nAtexakin alfa\n148637-05-2\nCilmostim\n154725-65-2\nEpoetin epsilon\n148363-16-0\nEpoetin omega\n102786-52-7\nEptacog alfa (activated)\n156679-34-4\nLenercept\n124146-64-1\nMobenakin\n0-00-0\nMoroctocog alfa\n148641-02-5\nMuplestim\n139076-62-3\nOctocog alfa\n3003 39 00\n0-00-0\nPlusonermin\n3003 90 90\n0-00-0\nFuladectin\n3507 90 90\n143831-71-4\nDornase alfa\n154248-97-2\nImiglucerase\n149394-67-2\nLedimase\n156616-23-8\nMonteplase\n159445-63-3\nNateplase\n155773-57-2\nPegorgotein\n3911 90 19\n95522-45-5\nColestilan\n31512-74-0\nPolixetonium chloride\n3913 90 80\n39464-87-4\nBetasizofiran\n0-00-0\nCertoparin sodium\n0-00-0\nMinolteparin sodium\nANNEX II\nAdditional pharmaceutical intermediates, i.e. compounds used for the manufacture of finished pharmaceutical products, to receive duty-free treatment\nCN code\nCAS RN\nName\n2843 30 00\n12192-57-3\n(alpha-D-glucopyranosylthio) gold\n2903 69 90\n42074-68-0\n1-chloro-2-(chlorodiphenylmethyl) benzene\n76283-09-5\nalpha,4-dibromo-2-fluorotoluene\n2906 29 90\n104265-58-9\n2-[(1 S,2R)-6-fluoro-2-hydroxy-1 -isopropyl-1,2,3,4-tetrahydro-2-naphthyl] ethyl p-toluenesulfonate\n2907 29 90\n700-13-0\n2,3,5-tximethylhydroquinone\n2909 50 90\n63659-16-5\n4-[2-(cyclopropylmethoxy) ethyl] phenol\n2914 40 90\n80-75-1\n11-alpha-hydroxypregn-4-ene-3,20-dione\n2914 50 00\n2107-69-9\n5,6-dimethoxyindan-1 -one\n24916-90-3\n9-beta,11-beta-epoxy-17,21-dihydroxy-l6-alpha-methylpregna-l,4-diene-3,20-dione\n2914 70 90\n83881-08-7\n21-chloro-9-beta, 11 -beta-epoxy-17-hydroxy-16-alpha-methylpregna-1,4-diene-3,20-dione\n2915 39 90\n979-02-2\n20-oxopregna-5,l 6-dien-3-beta-yl acetate\n2915 90 20\n638-41-5\npentyl chloroformate\n2916 39 00\n49708-81-8\ntrans-4-(p-chlorophenyl)cyclohexanecarboxylic acid\n2917 19 90\n48059-97-8\n(E)-oct-4-ene-1,8-dioic acid\n71170-82-6\ntriethyl 3-bromopropane-1,1,1-tricarboxylate\n2917 39 80\n27932-00-9\nindan-5-yl hydrogen phenylmalonate\n2918 13 00\n2743-38-6\ndibenzoyl-L-tartaric acid\n2918 17 00\n4358-88-7\nethyl DL-mandelate\n2918 19 80\n56188-04-6\n{(1 R,3R,5S)-3,5-dihydroxy-2-[(E)-(3S)-3-hydroxyoct-1 -enyl]cyclopentyl}acetic acid\n2918 29 90\n167678-46-8\n3-chloroformyl-o-tolyl acetate\n2918 30 00\n56105-81-8\n(R)-2-(3-benzoylphenyl) propionic acid\n22161-86-0\n(RS)-2-(3-benzoylphenyl) propionic acid\n78834-75-0\nenthyl 7-chloro-2-oxoheptanoate\n1944-63-4\n3-[(3aS,4S,7aS)-7a-methyl-1,5-dioxooctahydro-1 H-inden-4-yl]propionic acid\n39562-17-9\nmethyl 2-(3-nitrobenzylidene)-3-oxobutyrate\n2918 90 90\n26159-31-9\n(RS)-2-(6-methoxy-2-naphthyl)propionic acid\n105560-93-8\nmethyl (2R,3S)-2,3-epoxy-3-(4-methoxyphenyl) propionate\n40098-26-8\nmethyl 7-[(3RS)-3-hydroxy-5-oxocyclopent-1-enyl]heptanoate\n2921 19 80\n4261-68-1\n(2-chloroethyl) diisopropylamine hydrochloride\n2921 59 90\n122-75-8\nN, N'-dibenzylethylenediammonium di (acetate)\n2922 19 00\n126456-43-7\n(1S,2R)-1-aminoindan-2-ol\n68047-07-4\n4'-[2-(dimethylamino) ethoxy]-2-phenylbutyrophenone\n2922 30 00\n784-38-3\n2-amino-5-chloro-2'-fluorobenzophenone\n156732-13-7\n(S)-5-amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one\n2922 49 70\n37441-29-5\n5-amino-2,4,6-triiodoisophthaloyl dichloride\n42854-62-6\nbenzyl L-alaninate--p-toluenesulfonic acid (1:1)\n39878-87-0\n(-)-alpha-(chloroformyl) benzylammonium chloride\n54527-73-0\n2-(N-methylbenzylamino) ethyl 3-aminobut-2-enoate\n81677-60-3\nmethyl (4-nitrophenyl)-L-alaninate\n949-99-5\n3-(4-nitrophenyl)-L-alanine\n2924 10 00\n153758-31-7\n(2S)-2-amino-3-hydroxy-N-pentylpropionamide--oxalic acid (1:1)\n138531-07-4\nL-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-o\nL-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine\n2924 29 90\n40188-45-2\n3'-acetyl-4'-hydroxybutyranilide\n1149-26-4\nN-(benzyloxycarbonyl)-L-valine\n116661-86-0\n(2S,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutyric acid\n144163-85-9\ntert-butyl [(1S,3S,4S)-4-amino-1-benzyl-3-hydroxy-5-phenylpentyl] carbamate\n149451-80-9\ntert-butyl [(1S,2S)-1-benzyl-2,3-dihydroxypropyl] carbamate\n98737-29-2\ntert-butyl {(S)-alpha-[(S)-oxiranyl]phenethyl}carbamate\n0-00-0\n2-chloro-N-[2-(2-chlorobenzoyl)-4-nitrophenyl] acetamide\n125971-96-2\n2-[alpha-(4-fluorobenzoyl)benzyl]-4-methyl-3-oxovaleranilide\n32981-85-4\nmethyl (2R,3S)-3-benzamido-2-hydroxy-3-phenylpropionate\n2925 19 80\n151860-15-0\nmeso-N-benzyl-3-nitrocyclopropane-1,2-dicarboximide\n97338-03-9\nethyl (S)-3-(4-aminopheynl)-2-phthalimidopropionate hydrochloride\n94213-26-0\nethyl (S)-3-{4-[bis(2-chloroethyl)amino]phenyl}-2-phthalimidopropionate hydrochloride\n2926 90 80\n58311-73-2\n(Z)-(2-cyanovinyl)trimethylammonium p-toluenesulfonate\n133481-10-4\nethyl (l-cyanocyclohexl)acetate\n123632-23-5\n4-(2,2,3,3-tetrafluoropropoxy)cinnamonitrile\n2928 00 90\n94213-23-7\n(Z)-[cyano(2,3-dichlorophenyl)methylene]carbazamidine\n2930 90 16\n159453-24-4\nN-(benzyloxycarbonyl)-S-phenyl-L-cysteine\n2930 90 70\n159878-02-1\nbenzyl (1 R,2S)-3-chloro-2-hydroxy-1 -(phenylthiomethyl)propylcarbamate\n136511-43-8\nethyl N-{2-[(acetylthio)methyl]-3-(o-tolyl)-1-oxopropyl}-L-methionate\n2932 19 00\n97148-39-5\nammonium (Z)-2-methoxyimino-2-(2-furyl)acetate\n2932 29 80\n517-23-7\nalpha-acetyl-gamma-butyrolactone\n6559-91-7\n4'-demethylepipodophyllotoxin\n39521-49-8\n(3aR,4bS,4R,4aS,5aS)-4-(5,5-dimethyl-1,3-dioxolan-2-yl)hexahydrocyclopropa[3,4]cyclopenta[l,2-b]furan-o 2(3H)-one\n39746-01-5\n(3aR,4R,5R,6aS)-4-formyl-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl benzoate\n976-70-5\n3-oxopregn-4-ene-21,17-alpha-carbolactone\n2932 99 50\n32981-86-5\n10-deacetylbaccatin III\n2932 99 70\n7512-17-6\n2-acetamido-2-deoxy-beta-D-glucopyranose\n79944-37-9\ntrans-6-amino-2,2-dimethyl-1,3-dioxepan-5-ol\n125971-94-0\ntert-butyl [(4R,6R)-6-(cyanomethyl)-2,2-dimethyl-1,3-dioxolan-4-yl]acetate\n467-55-0\n3-beta-hydroxy-5-alpha-spirostan-12-one\n533-31-3\n3,4-(methylenedioxy)phenol\n2933 11 90\n6150-97-6\nmagnesium bis [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1 H-pyrazol-4-yl)methylamino]methane- sulfonate\n2933 19 90\n27511-79-1\n3-aminopyrazole-4-carboxamide hemisulfate\n2933 29 90\n4897-25-0\n5-chloro-1-methyl-4-nitroimidazole\n2933 39 95\n142057-79-2\n(RS)-2[(1 -benzyl-4-piperidyl)methyl]-5,6-dimethoxyindan-l -one\n120014-07-5\n2-[(l-benzyl-4-piperidyl)methylene]-5,6-dimethoxyindan-1-one\n6935-27-9\nbenzyl(2-pyridy l)amine\n87848-95-1\n6-bromo-2-pyridyl-p-tolyl ketone\n32998-95-1\nN-(tert-butyl)-3-methylpyridine-2-carboxamide\n84449-80-9\n1-[2-(4-carboxyphenoxy)ethyl]piperidinium chloride\n83949-32-0\n4-carboxy-4-phenylpiperidinium p-toluenesulfonate\n38092-89-6\n8-chloro-6,11-dihydro-11-(l-methyl-4-piperidylidene)-5H-benzo[5,6]cyclohepta[l,2-b]pyridine\n31255-57-9\n3-[2-(3-chlorophenyl)ethyl]pyridine-2-carbonitrile\n107256-31-5\n3-[2-(3-chlorophenyl)ethyl]-2-pyridyl 1 -methyl-4-piperidyl ketone hydrochloride\n6298-19-7\n2-chloro-3-pyridylamine\n5424-11-3\n2,2-diphenyl-4-piperidinovaleronitrile\n108555-25-5\n1-[2-(4-methoxyphenyl)ethyl]-4-piperidylamine dihydrochloride\n4046-24-6\n5-(l -methyl-4-piperidyl)-5H-dibenzo[a,d]cyclohepten-5-ol hydrochloride\n139886-04-7\n1-methyl-1,2,5,6-tetrahydropyridine-3-carbaldehyde (E)-O-methyloxime hydrochloride\n70708-28-0\n1-(2-pyridyl)-3-(pyrrolidin-1-yl)-1-(p-tolyl)propan-1-ol\n1619-34-7\nquinuclidin-3-ol\n2933 40 10\n105956-96-5\n7-[3-(tert-butoxycarbonylamino)pyrrolidin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroc quinoline-3-carboxylic acid\n86393-33-1\n7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid\n112811-72-0\n1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid\n98349-25-8\nethyl 1 -cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate\n2933 40 90\n159878-04-3\nbenzyl (1S,2S)-3-[3S,4aS,8aS)-3-tert-butylcarbamoylperhydro-2-isoquinolyl]-2-hydroxy-1-(phenylthioc methyl)propylcarbamate\n159989-64-7\n(3S,4aS,8aS)-N-(tert-butyl)-2-[(2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl] perhydroisoquinoline-3-carboxamide\n159989-65-8\n(3S,4aS,8aS)-N-(tert-butyl)-2-[(2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl] perhydroisoquinoline-3-carboxamide—methanesulfonic acid (1:1)\n120578-03-2\n3-[(E)-2-(7-chloro-2-quinolyl)vinyl]benzaldehyde\n1087-69-0\n(9S,13S,14S)-3-methoxymorphinan hydrochloride\n64228-78-0\npentamethylene bis {3-[10-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-2-isoquinolyl] propionate]- -oxalic acid (1:2)\n2933 59 70\n75128-73-3\n2-[(2-acetamido-6-oxo-6,9-dihydro-1H-purin-9-yl)methoxy]ethyl acetate\n3056-33-5\nN-(9-acetyl-6-oxo-6,9-dihydro-1H-purin-2-yl)acetamide\n10310-21-1\n2-amino-6-chloropurine\n124832-31-1\n2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl N-(benzyloxycarbonyl)-L-valinate\n150378-17-9\n(2R,4S)-2-benzyl-5-[2-(tert-butylcarbamoyl)-4-(3-pyridylmethyl)piperazin-1-yl]-4-hydroxy-N-[(1S,2R)-2-hydroxyindan-1-yl]valeramide\n157810-81-6\n(2R,4S)-2-benzyl-5-[2-(tert-butylcarbamoyl)-4-(3-pyridylmethyl)piperazin-1-yl]-4-hydroxy-N-[(lS,2R)-c 2-hydroxyindan-1-yl]valeramide sulfate\n150323-35-6\n(3S)-1-(tert-butoxycarbonyl)-3-(tert-butylcarbamoyl)piperazine\n41202-32-8\n1-(2-chlorophenyl)piperazine hydrochloride\n13078-15-4\n1-(3-chlorophenyl)piperazine hydrochloride\n71-30-7\ncytosine\n149062-75-9\n1,3-dichloro-6,7,8,9,1 0,1 2-hexahydroazepino[2,1 -b]quinazoline hydrochloride\n41202-77-1\n1-(2,3-dichlorophenyl)piperazine hydrochloride\n56177-80-1\n2-ethoxy-5-fluoropyrimidin-4(1 H)-one\n112733-45-6\nethyl (7-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-l -yl)acetate\n59703-00-3\n4-ethyl-2,3-dioxopiperazine-l-carbonyl chloride\n64090-19-3\n1-(4-fluorophenyl)piperazine dihydrochloride\n147539-21-7\nisopropyl[2-(piperazin-1-yl)-3-pyridyl]amine\n35386-24-4\n1-(2-methoxyphenyl)piperazine\n5464-78-8\n1-(2-methoxyphenyl)piperazine hydrochloride\n145012-50-6\n(7RS,9aRS)-perhydropyrido[l,2-a]pyrazin-7-ylmethanol\n2210-93-7\n1-phenylpiperazinium chloride\n111641-17-9\n4-(piperazin-1-yl)-2,6-bis(pyrrolidin-1-yl)pyrimidine\n68-94-0\npurin-6(1 H)-one\n70849-60-4\n1-(o-tolyl)piperazine hydrochloride\n2933 69 80\n58909-39-0\ntetrahydro-2-methyl-3-thioxo-1,2,4-triazine-5,6-dione\n2933 79 00\n135297-22-2\n(3S,4R)-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]-4-[(lR,3S)-3-methoxy-2-oxocyclohexyl]azetidin-2-one\n141646-08-4\n1-|[(cyclohexyloxy)carbonyl]oxy}ethyl 1 -(1 -hydroxyethyl)-5-methoxy-2-oxo-1,2,5,6,7,8,8 a,8b-octahydroazeto*c [2,1 -a]isoindole-4-carboxylate\n132127-34-5\n(3R,4S)-3-hydroxy-4-phenylazetidin-2-one\n75363-99-4\np-nitrobenzyl (2R,5R,6S)-6-[(R)-1-hydroxyethyl]-3,7-dioxo-1-azabicyclo[3.2.0]heptane-2-carboxylate\n141316-45-2\npotassium 1 -(1 -hydroxyethyl)-5-methoxy-2-oxo-1,2,5,6,7,8,8 a,8b-octahydroazeto[2,1 -a]isoindole-4-carbc oxylate\n2933 90 60\n59467-64-0\n[7-chloro-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-yl]methylamine\n59469-29-3\n[7-chloro-5-(2-fluorophenyl)-2,3-dihydro-1 H-l,4-benzodiazepin-2-ylmethyl]ammonium bis(maleate)\n59467-69-5\n8-chloro-6-(2-fluorophenyl)-1-methyl-3a,4-dihydro-3H-imidazo[l,5-a][l,4]benzodiazepine\n59469-63-5\n7-chloro-5-(2-fluorophenyl)-3-methyl-2-(nitromethylene)-2,3-dihydro-1 H-1,4-benzodiazepine 4-oxide\n59467-63-9\n7-chloro-5-(2-fluorophenyl)-2(nitromethylene)-2,3-dihydro-1 H-1,4-benzodiazepine\n2933 90 95\n130404-91-0\nN-[(R)-2-({(R)-2-[(2-adamantyloxycarbonyl)amino]-3-(lH-indol-3-yl)-2-methyl-1-oxopropyl}amino)-1- phenylethyl]succinamic acid-1-deoxy-1-methylamino-D-glucitol (1:1)\n122536-48-5\n3-[(S)-3-(L-alanylamino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3- carboxylic acid hydrochloride\n122536-91-8\n7-{(S)-3-[(S)-2-(tert-butoxycarbonylamino)-1-oxopropylamino]pyrrolidin-1-yl}-1-cyclopropyl-6-fluoro-4- oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid\n134575-17-0\ntert-butyl meso-3-azabicyclo[3.1.0]hex-6-ylcarbamate\n122536-66-7\ntert-butyl [(S)-1-methyl-2-oxo-2-[(S)-pyrrolidin-3-ylamino]ethyl}carbamate\n140629-77-2\ntert-butyl [(RS)-pyrrolidin-3-yl] carbamate\n100361-18-0\n7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid\n38150-27-5\n5-chloro-2-[3-(hydroxymethyl)-5-methyl-4H-1,2,4-triazol-4-yl]ben2Ophenone\n36916-19-5\n5-chloro-2-(3-methyl-4H-1,2,4-triazol-4-yl)benzophenone\n54196-62-2\n2',5-dichloro-2-[3-(hydroxymethyl)-5-methyl-4H-1,2,4-triazol-4-yl]benzophenone\n54196-61-1\n2',5-dichloro-2-(3-methyl-4H-1,2,4-triazol-4-yl)benzophenone\n141113-28-2\n(E)-( + )-2-(2,4-difluorophenyl)-1 -[3-[4-(2,2,3,3-tetrafluoropropoxy)styryl]-1 H-1,2,4-triazol-1 -yl}-3-(1 H- 1,2,4-triazol-1-yl)propan-2-ol\n141113-41-9\n(R)-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1 -yl)propane-1,2-diol\n144034-80-0\ndimethyl{2-[5-(1 H-1,2,4-triazol-1-ylmethyl)indol-3-yl]ethyl}amine\n122665-86-5\nethyl [3-(cyanomethyl)-4-oxo-3,4-dihydrophthalazin-1 -yl]acetate\n41340-36-7\n2-(7-ethyl-lH-indol-3-yl)ethanol\n95885-13-5\n5-ethyl-4-(2-phenoxyethyl)-4H-1,2,4-triazol-3(2H)-one\n96107-94-7\nethyl 1 H-tetrazole-5-carboxylate, sodium salt\n96034-57-0\ntrans-4-hydroxy-1-(4-nitrobenzyloxycarbonyl)-L-proline\n160194-26-3\n2-iodo-4-(1 H-1,2,4-triazol-1-ylmethyl)aniline\n66635-71-0\nisopropyl 2,3-dihydro-1 H-pyrrolizine-1-carboxylate\n4928-88-5\nmethyl 1 H-1,2,4-triazole-3-carboxylate\n0-00-0\n1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid sulfate\n112193-77-8\n1,4,7,10-tetraazoniacyclododecane bis(sulfate)\n3641-08-5\n1 H-l,2,4-triazole-3-carboxamide\n4928-87-4\n1 H-1,2,4-triazole-3-carboxylic acid\n6969-71-7\n1,2,4-triazolo[4,3-a]pyridin-3(2H)-one\n2934 10 00\n171485-87-3\n2-[4-(2-amino-4-oxo-4,5-dihydrothiazol-5-ylmethyl)phenoxymethyl]-2,5,7,8-tetramethylchroman-6-yl acetate\n65872-41-5\n(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid\n64486-18-6\n(Z)-2-[2-(chloroacetamido)thiazol-4-yl]-2-(methoxyimino) acetic acid\n76823-93-3\n1-{4-[(2-cyanoethyl)thiomethyl]thiazol-2-yl}guanidine\n139340-56-0\n[5-[(Z)-3,5-di(tert-butyl)-4-hydroxybenzylidene]-4-oxo-4,5-dihydrothiazol-2-yl]ammonium methanec sulfonate\n64485-88-7\nethyl (Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino) acetate\n66339-00-2\nethyl 2-(hydroxyimino)-2-[2-(tritylamino)thiazol-4-yl]acetate hydrochloride\n88046-01-9\n2-guanidinothiazol-4-ylmethyl carbamimidothioate dihydrochloride\n154212-61-0\nN-[2-isopropylthiazol-4-ylmethyl(methyl)carbamoyl]-L-valine\n66215-71-2\n(Z)-2-methoxyimino-2-[2-(tritylamino)thiazol-4-yl] acetic acid\n154212-59-6\n4-nitrophenyl thiazol-5-ylmethyl carbonate hydrochloride\n38585-74-9\nthiazol-5-ylmethanol\n155213-67-5\nthiazol-5-ylmethyl (lS,2S,4S)-1-benzyl-2-hydroxy-4-{(2S)-2-[3-(2-isopropylthiazol-4-ylmethyl)-3-methyl ureido]-3-methylbutyramido}-5-phenylpentylcarbamate\n2934 20 50\n80756-85-0\nS-(benzothiazol-2-yl) (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminothioacetate\n2934 20 90\n87691-88-1\n1-(1,2-benzisothiazol-3-yl)piperazine hydrochloride\n2934 90 50\n111974-69-7\n2-{2-[4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl]ethoxy}ethanol\n42399-49-5\n(2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one\n2934 90 60\n115787-67-2\n2-(2-amino-5-nitro-6-oxo-1,6-dihydropyrimidin-4-yl)-3-(3-thienyl)propiononitrile\n117829-20-6\n2-amino-7-thenyl-1,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one hydrochloride\n112887-68-0\nN-{5-[(1,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)methylamino]-2-thenoyl}-L-glutamic acid\n161005-84-1\n(S)-N,N-dimethyl-[3-(2-thienyl)-3-(1-naphthyloxy)propyl]amine-phosphoric acid (1:1)\n104795-66-6\n3-isopropoxy-5-methoxy-N-(1H-tetrazol-5-yl)benzo[b]thiophene-2-carboxamide\n104795-67-7\n3-isopropoxy-5-methoxy-N-(1H-tetrazoI-5-yl)benzo[b]thiophene-2-carboxamide-1H-imidazole (1:1)\n104795-68-8\n3-isopropoxy-5-methoxy-N-(1H-tetrazol-5-yl)benzo[b]thiophene-2-carboxamide, sodium salt\n63675-74-1\n6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene\n138564-59-7\n5-methyl-2-(2-nitroanilino)thiophene-3-carbonitrile\n2934 90 70\n25229-97-4\n2-cyano-3-morpholinoacrylamide\n2934 90 80\n119221-49-7\n5-[(2-aminoethyl)amino]-2-(2-diethylaminoethyl)-2H-[1]benzothiopyrano[4,3,2-cd]indazol-8-ol\n147086-81-5\n(4S,6S)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]thiopyran-4-ol 7,7-dioxide\n2934 90 98\n58-61-7\nadenosine\n152305-23-2\n(S)-4-(4-aminobenzyl)oxazolidin-2-one\n71420-85-4\n7-amino-3-[1-(sulfomethyl)-1H-tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid, sodium salt\n29706-84-1\n3'-azido-3'-deoxy-5'-0-tritylthymidine\n51762-51-7\nbenzhydryl 3-hydroxy-7-(phenylacetamido)cepham-4-carboxylate\n110314-42-6\n5-[(benzofuran-2-ylcarbonyl)amino]indole-2-carboxylic acid\n131986-28-2\n3-(4-chloro-1,2,5-thiadiazol-3-yl)pyridine\n107452-89-1\nomega-conotoxin M VIIA\n126429-09-2\n2-(dichloromethyl)-4,5-dihydro-5-(4-mesylphenyl)oxazol-4-ylmethanol\n126813-11-4\n(4R,5R)-2-(dichloromethyl)-4,5-dihydro-5-(4-mesylphenyl)oxazol-4-ylmethanol\n4097-22-7\n2',3'-dideoxyadenosine\n139264-17-8\n(S)-4-{[3-(2-dimethylaminoethyl)-1H-indol-5-yI]methyl}oxazolidin-2-one\n110351-94-5\n(S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione\n140841-32-3\n6-[3-fluoro-5-(4-methoxytetrahydropyran-4-yl)phenoxymethyl]-1-methyl-2-quinolone\n94732-98-6\n1-(1-{3-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]propyl}-4-piperidyl)-2,3-dihydro-1H-benzimidazole-2-thione\n125995-03-1\n(4R,6R)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-4-hydroxy tetrahydro-2H-pyran-2-one\n131988-19-7\n3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1-methylpyridinium iodide\n147027-10-9\n(1R,2S,5R)-menthyl (2R,5S)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-1,3-oxathiolane-2-carboxylate\n147126-62-3\n(1R,2S,5R)-menthyl (2R,5R)-5-hydroxy-1,3-oxathiolane-2-carboxylate\n104218-44-2\n3'-O-mesyl-5'-O-tritylthymidine\n27255-72-7\n3-methyl-7-(phenylacetamido)-3-cephem-4-carboxylic acid\n0-00-0\n(1R,2S,3S,6R)-[(S)-1-phenylethyl]-3,6-epoxytetrahydrophthalimide\n32231-06-4\n1-piperonylpiperazine\n55612-11-8\n5'-O-tritylthymidine\n2935 00 90\n151140-66-8\n(4-amino-3-iodophenyl)-N-methylmethanesulfonamide\n112101-81-2\n5-[(R)-(2-aminopropyl)]-2-methoxybenzenesulfonamide\n120298-38-6\nN-(5,6-dihydro-6-methyl-2-sulfamoyl-4H-thieno[2,3-b]thiopyran-4-yl)acetamide 7,7-dioxide\n150975-95-4\n5-methanesulfonamidoindole-2-carboxylic acid\n84522-34-9\nsodium 4-[2-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulfonamide\n2939 10 00\n66820-84-6\n(RS)-tetrahydropapaverine hydrochloride\n2940 00 90\n13035-61-5\n1,2,3,5-tetraacetyl-beta-D-ribofuranose\n3824 90 64\n330-95-0\n1,3-bis(4-nitrophenyl)urea--4,6-dimethylpyrimidin-2-ol (1:1)\n104832-01-1\n(R)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline~dibenzoyl-L-tartaric acid (1:1)\n0-00-0\nIntermediate concentrate obtained from a genetically-modified Escherichia coli fermentation medium, containing human granulocyte-macrophage colony-stimulating factor; for use in the manufacture of medicaments of HS No 30.02\n0-00-0\nIntermediate concentrate obtained from a genetically-modified Escherichia coli fermentation medium, containing human interferon alpha-2b; for use in the manufacture of medicaments of HS No 30.02\n0-00-0\nIntermediate concentrates obtained from a Micromonospora inyoensis fermentation medium used for the manufacture of the antibiotics sisomicin (INN) and netilmicin (INN)\n0-00-0\nIntermediate concentrates obtained from a Micromonospora purpurea fermentation medium used for the manufacture of the antibiotics gentamicin sulfate (INNM) and isepamicin (INN)\n3824 90 95\n0-00-0\nethyl 7-chloro-2-oxoheptanoate, in the form of a solution in toluene\n3911 90\n162430-94-6\n1,6-hexanediamine, polymer with 1,10-dibromodecane\n3913 90 80\n83513-48-8\ndanaparoid sodium\nANNEX III\nAdditions to the list of prefixes and suffixes which, in combination with the INNs, describe salts, esters or hydrates of INNs\nN-acetylglycinate\nacistrate\nacoxil\namsonate\nbenzathine\nbezomil\nbuciclate\nbunapsilate\nbuteprate\nbutyl ester\ncarbesilate\np-chlorobenzenesulfonate\np-chlorobenzenesulphonate\nciclotate\ncipionate\nclosilate\nclosylate\ncrobefate\ncromacate\ncromesilate\ncyclopentanepropionate\ncyclotate\ncypionate\ndapropate\ndeanil\ndecil\ndibudinate\ndibunate\ndiethanolamine\ndigolil\nN,N-dimethyl-beta-alanine\ndiolamine\ndocosil\ndofosfate\nedamine\nedisylate\nepolamine\nerbumine\netabonate\nethanolamine\nethylenediamine\nfarnesil\nfendizoate\nfostedate\nhibenzate\nhybenzate\nhyclate\no-(4-hydroxybenzoyl)benzoate\nisocaproate\nlauril\nlaurilsulfate\nlaurilsulphate\nlauryl\nlaurylsulfate\nlaurylsulphate\nmegallate\nmetembonate\n4-methylbicyclo[2.2.2]oct-2-ene-l-carboxylate\nmofetil\noctil\nolamine\noxoglurate\npendetide\npivoxetil\nproxetil\nl-pyrrolidineethanol\nsodium lauril sulfate\nsodium lauril sulphate\nsodium lauryl sulfate\nsodium lauryl sulphate\nsteaglate\ntenoate\nteprosilate\ntetradecyl hydrogen phosphate\ntofesilate\ntriclofenate\ntriethanolamine\ntriflutate\ntrolamine\ntrometamol\ntromethamine\ntroxundate\nxinafoate\nANNEX IV\nINNs which shall no longer benefit from duty-free treatment\nCN code\nCAS RN\nName\n2903 22 00\n79-01-6\ntrichloroethylene\n2903 30 10\n811-97-2\nnorflurane\n2903 51 10\n58-89-9\nlindane\n2906 21 00\n100-51-6\nbenzyl alcohol\n2915 29 00\n82279-57-0\nzinc acetate, basic\n2922 41 00\n56-87-1\nlysine\n2922 42 90\n56-86-0\nglutamic acid\n2922 49 10\n56-40-6\nglycine\n2922 50 00\n72-19-5\nthreonine\n2923 10 10\n67-48-1\ncholine chloride\n2928 00 90\n79-17-4\npimagedine\n2930 90 20\n111-48-8\nthiodiglycol\n2933 90 95\n73-22-3\ntryptophan\n3102 70 10\n156-62-7\ncalcium carbimide\n3904 61 10\n9002-84-0\npolitef\n3906 90 90\n54182-57-9\ncarbomer\n3907 20\n0-00-0\nmacrogol ester\n3907 20 12\n25322-68-3\nmacrogol\n3907 20 21\n25301-02-4\ntyloxapol\n3907 60 10\n25038-59-9\npegoterate\n3908 10 00\n25038-54-4\npolicapram\n3910 00 00\n9006-65-9\ndimeticone\n3912 20 11\n9004-70-0\npyroxylin\n3912 31 00\n9000-11-7\ncarmellose\n3912 39 80\n8063-82-9\nhypromellose", "summary": "Duty-free treatment of specified pharmaceutical active ingredients\nDuty-free treatment of specified pharmaceutical active ingredients\nSUMMARY OF:\nRegulation (EU) No 1238/2010 – duty-free treatment of specified pharmaceutical active ingredients and products in finished pharmaceuticals\nRegulation (EC) No 467/97 – duty-free treatment of specified ingredients and products used in finished pharmaceuticals and withdrawing this treatment for others\nWHAT IS THE AIM OF THE REGULATIONS?\nThe regulations incorporate into European Union (EU) law duty-free decisions for certain pharmaceuticals and active ingredients. These were first taken in the Uruguay Round of international trade negotiations.\nThe items each have an international nonproprietary name (INN)* and new ones have been added to the lists on several occasions.\nRegulation (EU) No 1238/2010 updates the lists after the fourth review launched in 2009.\nCouncil Regulation (EC) No 467/97 updates the lists after the first review.\nKEY POINTS\nRegulation (EU) No 1238/2010\nIt amends Annex I (lists of pharmaceutical substances qualifying for duty-free treatment) to Regulation (EEC) No 2658/87 setting out the EU’s combined nomenclature.\nIt gives duty-free treatment from 1 January 2011 to: products with a World Health Organization international non-proprietary name (Annex I);the list of prefixes and suffixes which, combined with INNs, describe their salts, esters or hydrates which are also eligible for duty-free treatment (Annex II);pharmaceutical intermediates used to produce and manufacture finished pharmaceuticals (Annex III).\nIt removes certain pharmaceutical intermediates from the list of those receiving duty-free treatment (Annex IV).\nRegulation (EC) No 467/97\nIt gives duty-free treatment from 1 April 1997 to: 231 designated pharmaceutical active ingredients with an INN, along with their salts, esters and hydrates (Annex I);234 designated products used to produce and manufacture finished pharmaceuticals (Annex II).\nIt expands the list of specified prefixes and suffixes of INNs eligible by adding 84 names to duty-free treatment (Annex III).\nIt removes 25 products – together with their salts, esters and hydrates – from duty-free treatment since their use was predominantly non-pharmaceutical (Annex IV).\nFROM WHEN DO THE REGULATIONS APPLY?\nRegulation (EU) No 1238/2010 has applied since 1 January 2011.\nRegulation (EC) No 467/97 has applied since 14 March 1997.\nBACKGROUND\nDuring the Uruguay Round, the most important producers – the EU, the United States, Japan, Canada, Switzerland, Norway and China – agreed to reduce duties on pharmaceuticals to zero. The agreement covered over 6,000 products.\nWith the development of new drugs, reviews took place in 1995–1996, 1998 and 2006, adding almost 2,400 products. The fourth review added 718 new substances, bringing the total of duty-free pharmaceutical imports into the EU to 8,619.\nFor further information, see: International nonproprietary names programme and classification of medical products (World Health Organization).\nKEY TERMS\n              \nInternational nonproprietary names (INN). Also known as generic names, they identify pharmaceutical substances or active pharmaceutical ingredients. Each INN is a unique name that is globally recognised and that is classified as public property. The World Health Organization works closely with INN experts and national nomenclature committees to select a single name that is accepted worldwide for each active substance to be marketed as a pharmaceutical.\nMAIN DOCUMENTS\n            \nRegulation (EU) No 1238/2010 of the European Parliament and of the Council of 15 December 2010 amending Annex I to Council Regulation (EEC) No 2658/87 as regards the provision of duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals (OJ L 348, 31.12.2010, pp. 36–73).\nCouncil Regulation (EC) No 467/97 of 3 March 1997 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals and withdrawing duty-free treatment as pharmaceutical products from certain INNs whose predominant use is not pharmaceutical (OJ L 71, 13.3.1997, pp. 1–15).\nRELATED DOCUMENTS\n            \nCouncil Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (OJ L 256, 7.9.1987, pp. 1–675).\nSuccessive amendments to Regulation (EEC) No 2658/87 have been incorporated in the original text. This consolidated version is of documentary value only.\nlast update 14.12.2021", "tags": ["tariff nomenclature", "World Health Organisation", "chemical product", "pharmaceutical product", "product designation", "tariff exemption"], "subjects": ["Commercial policy", "CCT: derogations"], "split": "train", "reference_annotations": {}, "summary_annotations": {"31997R0467_p1": {"text": "regulation 1238/2010 of the European Parliament and of the Council of 15 December 2010 amending Annex I to Council regulation 2658/87 as regards the provision of duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals (OJ L 348, 31.12.2010, pp. 36–73).", "triples": [" regulation 1238/2010,  amending,  regulation 2658/87"]}}}